Replies to post #93632 on Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

You understand that AMGN took a flyer on NEO 30 months ago, right? It was a very cheap long term option for a program that could be valued in billions if works out. Something happened, and AMGN moved on.
Is this program worth more now? Most likely, it depends on what has become clearer now compared to August '17. The clinical data albeit a limited one should provide an answer for the BP looking at this program now. They have more clarity now thus the experts would be in a better position to put a price tag on it. We do not know the data, but the BP does. We shall see if they decide to take another swing at it. The problem is ADXS is not in a strong position to negotiate. We have so many self-inflicted wounds -- we are almost on a life support. Lowball offers could be accepted at this point that should not be even considered before. Time is money, and ADXS is running out of both.

[ignatiusrielly35]

HOT was an unknown construct at the time that Amgen signed the NEO deal. Amgen probably didn’t know it existed at the time. Then fast forward to ADXS rolling out HOT with Keytruda for a trial in NSCLC, cheaper and faster. Not hard to imagine that Amgen became peeved.